Summary It is well established that renal allograpft recipients (RARs) have an increased incidence of viral warts and premalignant and malignant cutaneous lesions, and the risk of their development increases in proportion to duration of graft survival. It has been postulated that, in addition to the effects of prolonged immunosuppression and previous sun exposure, human papillomaviruses (HPV) may also contribute to the carcinogenic process. In this study, the prevalence of HPV DNA was examined in a range of premalignant and malignant cutaneous tumours from 50 immunosuppressed patients (47 renal allograft recipients plus three cardiac allograft recipients) and 56 immunocompetent patients using Southern hybridisation as a lowstringency screening method and type-specific polymerase chain reaction (PCR) assays for eight HPV types. The combined results for renal allograft recipients show that HPV DNA was detectable in 79% of viral warts, 42% of premalignant keratoses, 33% of intraepidermal carcinomas, 43% of invasive squamous cell carcinomas and 16% of uninvolved skin specimens (squamous cell carcinomas/renal allograft recipients significantly different at P <0.05 from uninvolved skin specimens/renal allograft recipients). In immunocompetent patients the pattern of HPV DNA prevalence was 100% for viral warts; 25% for keratoses, 23% for intraepidermal carcinomas, 22% for squamous cell carcinomas and 8% for uninvolved skin. No single HPV type predominated in tumour specimens from either group. More tumours were found to contain HPV DNA by Southern hybridisation analysis than PCR, indicating the presence of HPV types other than HPV 1, 2, 5, 6, 8, 11, 16 and 18 in some tumours. However, 'low cancer risk' HPV types 1, 2 and 6 as well as 'high cancer risk' HPV types 5 and 16 were specifically detected by PCR in a small number of neoplasms. These data suggest that multiple HPV types may contribute to cutaneous neoplasia in RARs and that they appear to act early in the process of carcinogenesis, perhaps by functioning as tumour promoters via stimulation of cell proliferation.
Renal transplantation is now a well-established procedure, with many recipients surviving 20 years or more. However, a major problem associated with long-term immunosuppression is the increased prevalence of various malignancies, especially in skin, anogenital tract and lymphoreticular system (Hoxtell et al., 1977; Birkeland, 1983; Blohme & Larko, 1984; Sheil et al., 1985; Shuttleworth et al., 1987; Alloub et al., 1989) . Moreover, renal allograft recipients (RARs) frequently develop a spectrum of cutaneous complications ranging from benign viral warts (VWs), to verrucous and actinic keratoses (Ks) exhibiting varing degrees of dysplasia, culminating in squamous cell carcinoma (SCC) (Benton et al., 1992) . The prevalence and morbidity of such complications increases the longer the duration of immunosuppression with a number of long-standing RARs developing multiple skin tumours . In RARs squamous cell cancers outnumber basal cell cancers (BCCs) by a ratio of 15: 1, a reversal of the 1:5 ratio normally observed in immunocompetent patients.
A number of factors have been implicated in the development of skin cancers in RARs. Ultraviolet (UV) radiation is known to be of considerable importance as the majority of tumours occur on sun-exposed skin (Blohme & Larko, 1984; Boyle et al., 1984; Baadsgaard, 1991; Streilein, 1991) . The alteration in cell-mediated immunity brought about by prolonged immunosuppressive therapy is thought to be a contributory factor and is associated with an increased incidence of anogenital cancers and lymphomas as well as skin tumours (Streilein, 1991) . The possible association with human papillomaviruses (HPVs) is derived indirectly from observations in the rare, inherited skin disease epidermodysplasia verruciformis (EV) (Orth et al., 1979; Orth, 1986) . This disease is characterised by the development of extensive, persistent infection with unusual HPV types and a predisposition to cutaneous SCC on light-exposed skin in around one-third of patients (Pfister et al., 1983a; Fuchs & Pfister, 1990) . Although over 20 HPV types have been detected in benign skin lesions from EV patients, in SCC HPV types 5 and 8 are consistently demonstrated (Orth et al., 1986; Fuchs & Pfister, 1990) . However, in contrast to the HPV types 16 and 18 that are usually integrated in squamous cervical cancers, the majority of EV-associated SCCs contain HPV 5 or 8 DNA in an episomal form, with integration being a rare event (Yabe et al., 1989) .
There is also some direct evidence to suggest that HPV may play a part in the development of skin cancers in RARs Benton et al., 1992) . Histologically, viral warts and keratotic lesions in RARs often exhibit varying degrees of epidermal dysplasia, while SCCs develop on a background of verrucous keratoses and may retain HPVassociated features. However, the detection of HPV DNA in the cutaneous SCC of RARs has been somewhat controversial, with EV-associated types and a variety of common cutaneous and genital HPV types being identified in some, but not all, studies (Lutzner et al., 1980; Van der Leest et al., 1987; Barr et al., 1989; Dyall-Smith et al., 1991; Soler et al., 1992) .
We report here the results of an investigation in which we determined, first, the prevalence of HPV DNA in various cutaneous lesions from RARs and immune-competent patients (ICPs) by Southern hybridisation analysis with mixed probes for common cutaneous and EV-associated HPV types. Second, using type-specific and sensitive PCR assays we determined the prevalence of the putative oncogenic HPV types 5 and 8, the more common cutaneous HPV types 1 and 2 and the common genital HPV types 6, 11, 16 and 18. Finally, we considered whether the pattern of HPV prevalence in the cutaneous lesions provided clues as to the stage at which HPV may act in the oncogenic process.
Materials and methods

Patients
Two groups of patients were investigated. The first comprised 47 immunosuppressed patients, 44 RARs plus three cardiac allograft recipients (mean age 50 years, range 20-71 years), all of whom received transplants between 1965 and 1992 (mean duration of transplant 10.9 years, range 1-26 years). Prior to 1984 patients received immunosuppressive therapy with prednisolone and azathioprine, but since then all new allograft recipients have been treated with prednisolone and cyclosporin A, a few subsequently being switched to azathioprine. The second patient group comprised 56 immunocompetent individuals (mean age 66.6 years, range 22-90 years) who were referred for treatment of suspected warts or skin malignancies. All patients were treated in the Department of Dermatology at the Royal Infirmary of Edinburgh.
Tissue collection and DNA extraction Therapeutic skin biopsies were collected from RARs (120 in all) and ICPs (63). A 6 mm biopsy of uninvolved, sun-exposed, forearm skin was also obtained from 19 RARs (some with and others without skin tumours elsewhere) and 12 healthy ICPs who volunteered to undergo this procedure. Immediately following excision, each lesion was bisected longitudinally with a sterile blade to minimise the risk of contamination: half was snap frozen in liquid nitrogen prior to DNA extraction while the remainder was fixed in formalin or periodate -lysine-paraformaldehyde-dichromate (PLPD) (Holgate et al., 1986) for histological examination. Frozen tissue was minced in lysis buffer (50 mM Tris, 50 mM EDTA, 100 mm sodium chloride, 5 mM DTT, 1% SDS, 1.5mg ml' proteinase K) and DNA extracted using a standard phenolchloroform extraction technique (Sambrook et al., 1989) .
Histopathology
The cutaneous lesions were assessed for standard morphological features suggestive of actinic damage and for degrees of dysplasia progressing to intraepidermal and invasive carcinoma .
Polymerase chain reaction (PCR) Oligonucleotide primers, situated in E6, were designed from published sequence data (Danos et al., 1982; Fuchs et al., 1986; Zachow et al., 1987; Hirsch-Behnam, 1990 ) to detect HPV types 1, 2, 5 and 8 in type-specific assays (Table I) .
Primer sequences for HPV types 6, 11, 16 and 18 were validated in previous studies (Arends et al., 1991) . Prior to amplification with HPV primers, each sample was amplified with control ras primers to confirm adequate preservation of DNA (Table I) to amplify HPV types 1, 2, 5 and 8 were as follows: One cycle of 94°C for 5 min; 30 cycles of 58°C (55°C for HPV 1) for 2 min, 72°C for 3 min and 94°C for 1 min; and one cycle of 58°C (55°C for HPV 1) for 2 min and 72°C for 10 min. Positive (1 pg of purified HPV plasmid DNA instead of genomic DNA) and negative (template-free) controls were included with all reactions. Amplified products were visualised on a 2% Nusieve-Seakem (3:1) agarose gel containing 0.5 ig ml-' ethidium bromide (Flowgen Instruments, Kent, UK).
Southern hybridisation analysis Genomic DNA (8-1Ong) was digested using the restriction enzyme BamHI (NBL). Following electrophoresis on 8% agarose gel, DNA was alkaline denatured and transferred on to charged nylon membrane (Hybond N+, Amersham, Aylesbury, UK) according to the manufacturer's instructions. HPV probe DNA was isolated from vector DNA by digestion with the appropriate restriction enzyme followed by electrophoresis on a 0.8% low melting temperature agarose gel. The resulting HPV DNA was purified using Biorad Prepagene kit (Biorad Laboratories, Richmond, UK) and 25 ng DNA of each HPV type was prepared and labelled with 32P using the Amersham Multiprime kit as specified by the manufacturer's instructions. Hybridisation was carried out at Tm -40°C (55°C) (hybridisation buffer consisted of 6 x SSC, 1% SDS and 0.1 g ml-' dextran sulphate) using mixed HPV probes containing 25ng each of either HPV types 3, 8 and 13 or HPV types 2, 4 and 12. The minimum specific activity of all probes was 4-5 x 106 c.p.m. ml-'. All filters included positive (HPV plasmid DNA) and negative (placental DNA) controls. Following hybridisation, filters were washed at low stringency [2 x SSC, 1% SDS, at 55°C for 30 min (Tm -35°C)] and exposed to X-ray film initially for 24 h and subsequently for 3 days. Cases positive for HPV by this intial screen were further analysed by Southern hybridisation using the restriction enzyme PstI. Filters containing 50 pg of purified HPV plasmid DNA of types 1, 2, 3, 4, 5, 8, 10, 12, 13, 14, 17, 19 and 20 (Heilman et al., 1980; Ostrow et al., 1982 Ostrow et al., , 1983 Kremsdorf et al., 1983 Kremsdorf et al., , 1984 Pfister et al., 1983a, b; Gassenmaier et al., 1984) mixed with 10 gAg of genomic DNA were also made for use in initial optimisation experiments. The sensitivity of this technique was investigated by performing Southern hybridisation analyses on serially diluted HPV 16 plasmid DNA mixed with a known concentration of genomic DNA.
Results
Prevalence screen for HPV DNA by Southern hybridisation Initial experiments indicated that, by using Southern hybridisation with a probe cocktail containing a mixture of HPV types 3, 8 and 13 at low hybridisation (Tm -40'C) and washing (Tm -35°C) stringency, it was possible to detect HPV types 1, 2, 3, 4, 5, 8, 10, 12, 13, 14, 17, 19 and 20 . The probe cocktail containing HPV types 2, 4 and 12 was also extensively used, but added little extra information. The sensitivity of Southern hybridisation analysis was found to be 5 pg of viral DNA in a background of 10 tg of genomic DNA, equivalent to 0.1 copies per cell.
A total of 108 skin biopsies from RARs, including over 50 IEC and SCC specimens from 16 patients, together with 63 specimens from ICP were analysed by Southern hybridisation, using the mixed probe cocktail described above to screen for the presence of HPV DNA. As expected, detection of HPV DNA was greatest in VWs (64%), but 25% of keratoses, 24% of IECs and 33% of SCCs from RARs contained HPV DNA (Figure 2 and Table II ). All specimens from normal skin were negative for HPV DNA. Lesions from ICPs showed lower HPV DNA prevalence than those from RARs, except for viral warts, only five of which were examined from ICPs (Table II) 3, 4, 5, 8, 10, 12, 14, 17, 19 and 20 , and found to be absolutely type specific.
A total of 118 specimens from RARs and 48 from ICPs, were analysed by type-specific PCR for HPV types 1, 2, 5 and 8 (Tables III and IV ). In each sample c-Ki-ras sequences could be detected with appropriate ras primers (data not shown). Relatively few specimens were positive for HPV DNA compared with results by Southern hybridisation analysis. In particular, HPV 5 DNA was only present in a small number of benign and premalignant lesions from RARs and ICPs but in no SCCs. HPV 8 DNA was found in only one SCC from an ICP. HPV 1 and 2 DNA was found in both benign and malignant lesions from RARs and ICPs (Tables III and IV) . A total of 102 lesions from RARs and 43 from ICPs were further tested for the common genital HPV types 6, 11, 16 and 18 by type-specific PCR (Tables III  and IV) . 'High-risk' HPV 16 DNA was detected in uninvolved skin from an RAR, and 'low-risk' HPV 6 DNA was present in an SCC from an RAR. Four VWs from RARs contained more than one HPV type (5 and 2, 5 and 6, 5 and 11, 2 and 11). Rigorous anti-contamination procedures were followed throughout (Arends et al., 1991) type-specific PCR, only three were positive by Southern hybridisation analysis (Table V) . A combination of both detection assays resulted in 11/14 (79%) VWs, 10/24 (42%) Ks, 7/21 (33%) IECs, 13/30 (43%) SCCs and 3/19 (16%) USs from RARs containing HPV DNA (Table VI) . The combined results for ICPs gave HPV prevalences of 5/5 (100%) for VWs, 2/8 (25%) for Ks, 3/13 (23%) for IECs, 2/9 (22%) for SCCs and 1/12 (8%) for USs. No statistically significant differences by the chi-squared test were found comparing HPV prevalence in each histological group between ICPs and RARs. However, SCCs from RARs showed a significantly higher HPV prevalence (P<0.05) than uninvolved skin from RARs. Overall, HPV DNA was detected with greater frequency by Southern hybridisation analysis than by typespecific PCR (Tables II, III and IV) . Some patients showed a high susceptibility to developing multiple malignant tumours exhibiting different HPV DNA content (Table V) , but there was no specific pattern of combination of HPV types in these lesions.
Discussion
Prevalence of HP V DNA in the spectrum of cutaneous neoplasia in RAR Compelling evidence exists of a contributory role for 'highrisk' genital HPV types 16 and 18 in the development of SCC of the genital tract (Arends et al., 1990 (Arends et al., , 1991 (Arends et al., , 1993 zur Hausen, 1991; Lorincz et al., 1992) . Similarly, in EV the role of HPV 5 and 8 in the aetiopathogenesis of cutaneous SCC is suggested by their presence in over 90% of cancers (Orth et al., 1979; Orth, 1986) . Furthermore, HPV types 5, 8, 16 and 18 can cooperate with activated ras to transform rodent cells (Watts et al., 1984; Iftner et al., 1988; Fuchs & Pfister, 1990) . By contrast, investigation of the relationship between HPV and cutaneous cancers in RARs has been inconclusive with regard to both prevalence and type of HPV DNA detected. This may be the result of differences in sample size studied or differences in sensitivity and specificity of the detection (Lutzner et al., 1980 (Lutzner et al., , 1983 Rudlinger et al., 1986; Jablonska et al., 1987; Van der Leest, 1987; Blessing et al., 1989; Euvrard et al., 1991 ). An additional factor in some studies may be the inclusion of a large proportion of patients who seem to be at exceptionally high risk of developing multiple and widespread premalignant and malignant cutaneous lesions with increased HPV DNA content . To overcome some of these problems we have studied a large, unselected series of RARs using both Southern hybridisation and type-specific PCR techniques.
The prevalence of HPV DNA was closely similar throughout the spectrum of cutaneous neoplasia in RARs: 42% of keratoses, 33% of IECs and 43% of SCCs contained HPV DNA, but only 16% of uninvolved skin was positive (Table  VI) , not dissimilar to some other reports (Soler et al., 1992) . This pattern differs from that found in cervical neoplasia in which the prevalence of HPV (of specific 'high-risk' types) increases throughout the cervical intraepithelial neoplasia spectrum (Stanley, 1990; Arends et al., 1991 Arends et al., , 1993 Lorincz et al., 1992) . These findings suggest that, if HPV play a role in cutaneous neoplasia of RARs, this must involve the early stages of the neoplastic process. One hypothesis is that HPVs may act as tumour promoters by stimulating cell proliferation. Thus, HPV may provide a stimulus analogous to that of phorbol esters in traditional rodent skin carcinogenesis models, in which promotion of cell proliferation fixes irreversibly any genetic mutations induced by initiating agents such as chemical carcinogens or UV light. The role of promoter for HPV was previously suggested by zur Hausen (1982) , and the ability to induce keratinocyte proliferation is common to the many different types of common cutaneous and EVassociated HPV, as evidenced by the variety of warts that they cause. This hypothesis is supported by the clinicopathological observations that RARs frequently exhibit extensive warts and verrucous keratoses, as well as malignant tumours: these lesions form a seamless spectrum of histological change, with many keratoses (actinic and verrucous) showing dysplasia, and both IECs and SCCs retaining viral features. Furthermore, these immunosuppressed patients appear to have relatively high background levels of HPV, indicated by our findings that 3 out of 19 (16%) biopsies from the apparently uninvolved skin of RARs contained HPV DNA, in two cases HPV 5 DNA and in one HPV 16 DNA. Such a background level of HPV infection of skin, in the presence of long-term immunosuppression that is likely to permit viral persistence over a prolonged period, together with sun-induced DNA damage, may give rise to conditions conducive to tumour induction. Moreover, the usual 1:5 ratio of SCC-BCC is reversed in RARs to 15:1, suggesting that HPVs encourage squamous rather than basal cell neoplastic differentiation.
Specific HPV types found in cutaneous neoplasms in RAR In this study we were not always able to characterise fully the HPV types found by Southern hybridisation analysis. However, the results of type-specific PCR analysis indicate that only a small proportion of lesions contained HPV 5 or 8 DNA. This is in contrast to previous findings from SE Scotland , where 15 out of 25 SCCs were found to contain HPV5 or 8 DNA. That study used mostly dot blotting to detect HPV 5 or 8 DNA, which does not exclude the possibility of cross-hybridisation with other EVassociated HPV types. Moreover, all 15 positive specimens in that study came from four patients at exceptionally high risk of development of cutaneous lesions, each of whom had multiple SCCs. The balance of evidence now suggests that HPV 5 and 8 DNA is found relatively infrequently in tumours from RARs (Lutzner et al., 1980 (Lutzner et al., , 1983 Rudlinger et al., 1986; Van der Leest, 1987; Soler et al., 1992) .
It is of interest that we found both HPV 1 and 2 DNA by PCR in a small number of SCCs in this series. These HPV types were previously considered to be non-transforming, and usually associated with benign skin warts. Recent work has also emphasised the importance of extending investigations of HPV content to include the anogenital HPV types (Ostrow et al., , 1989 Stone et al., 1987; Eliezri et al., 1990; Ashinoff et al., 1991) . Two positive SCCs in the present study, one containing HPV 6 and the other HPV 16 DNA, both came from a female RAR who in addition to multiple cutaneous SCCs has developed SCCs of cervix, vulva and anal canal. HPV 16 DNA has also been detected in her genital tumours. Overall, from the present investigation using both Southern hybridisation and PCR, the emerging pattern of HPV type prevalence is one of involvement by multiple HPV types.
Some cases found to contain HPV sequences by PCR could not be confirmed by Southern hybridisation analysis, indicating that in many cases copy numbers of HPV genomes were too low to be detected by Southern analysis. Not surprisingly, the absolutely type-specific PCR assays for HPV 1, 2, 5, 6, 8, 11, 16 and 18 did not detect other HPV types found by Southern hybridisation. In a pilot study applying a consensus PCR assay (Manos et al., 1989) , primarily designed to detect genital HPV types, the common cutaneous and EV-associated HPV types were poorly detected even when using cloned HPV plasmid DNA as template (unpublished data). Thus, it is possible that this and other studies have underestimated the true HPV prevalence in cutaneous neoplasms in RARs, owing to a combination of a wide variety of HPV types involved and low copy number of HPV genomes.
The overall pattern found in this study is of similar HPV prevalence throughout the spectrum of cutaneous neoplasia in RARs. Furthermore, studies of the prevalence of accurately typed specific HPV have shown that no single HPV type predominates in cutaneous lesions in RARs with multiple HPV types being detected. At a practical level, these data challenge the necessity to systematically type HPV DNA found in cutaneous lesions in RARs. Our observations are consistent with the hypothesis that in RARs multiple HPV types play a role in carcinogenesis by promotion of cell proliferation, and this hypothesis merits further testing.
